OrthoPediatrics Amends Credit Agreement, Secures New $20M Delayed Draw Facility with Challenging Terms

summarizeSummary

OrthoPediatrics Corp. amended its credit agreement, replacing a $25M delayed draw facility with a new $20M delayed draw facility, reducing total potential committed capital by $5M. The new facility extends availability but features high interest, a PIK option, and a challenging EBITDA condition for drawing funds.

check_boxKey Events

• New Delayed Draw Term Loan Facility

  The company established a new delayed draw term loan facility for up to $20.0 million, replacing a previous $25.0 million delayed draw commitment. This results in a net reduction of $5.0 million in total potential committed capital.

• Extended Availability Period

  The new delayed draw facility is available for drawing until June 30, 2027, extending the previous availability period which expired on August 5, 2025.

• Challenging Financing Terms

  The facility features an interest rate of SOFR plus 6.50% (with a 3.25% floor) and includes a company option for a 1.00% payment-in-kind (PIK) interest, indicating expensive capital and a focus on cash conservation.

• EBITDA Condition for Drawing Funds

  A critical condition for drawing on the new facility is achieving an EBITDA of at least $15.0 million for the most recently ended Test Period, which may be difficult given the company's recent increased net losses.

auto_awesomeAnalysis

OrthoPediatrics Corp. has amended its Credit Agreement and Guaranty, establishing a new delayed draw term loan facility of up to $20.0 million. This new facility replaces a previous $25.0 million delayed draw commitment, resulting in a net reduction of $5.0 million in the company's total potential committed capital (from $50.0 million to $45.0 million). While the new facility extends the availability period for drawing funds until June 30, 2027 (from August 5, 2025), the terms are notably challenging. The interest rate is set at SOFR plus 6.50% (with a 3.25% floor), and the company has an option to make a payment-in-kind (PIK) interest payment equal to 1.00% per annum, indicating a desire to conserve cash. Furthermore, access to these funds is conditional on the company achieving an EBITDA of at least $15.0 million for the most recently ended Test Period. Given the company's reported 'increased net losses' and 'operational challenges' in its recent 10-K, meeting this EBITDA covenant could be a significant hurdle, making the actual availability of these funds uncertain. This financing, while providing some liquidity runway, comes at a high cost and with restrictive conditions, against a backdrop of recent insider selling.